Maia Biotechnology Inc. has advanced its telomere-targeting molecule program (Project T3) with the nomination of a lead new molecular entity candidate (MAIA-2021-20) and a back-up new molecular entity candidate (MAIA-2022-12) for progression into preclinical GLP-toxicity and other studies. One of these candidates may then be advanced into clinical trials upon completion of the preclinical evaluations.